Qube Research & Technologies Ltd
Position in DSGN — Design Therapeutics, Inc.
CIK 1729829
LONDON, X0
Position in DSGN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$363,707
+$353,704 QoQ
Shares Held
34,183
+1044.8% QoQ
Ownership
0.055%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2021
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in DSGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Qube Research & Technologies Ltd holds $2,034,188,909 across 187 Biotechnology names. DSGN ranks #144 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
838,187 | $277,330,932 | |
| 2 | FOLD |
AMICUS THERAPEUTICS, INC.
|
8,809,340 | $127,383,056 | |
| 3 | ROIV |
Roivant Sciences Ltd.
|
3,450,904 | $95,590,040 | |
| 4 | RPRX |
Royalty Pharma plc
|
1,524,511 | $73,130,792 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
83,358 | $64,405,725 | |
| 6 | AXSM |
Axsome Therapeutics, Inc.
|
335,334 | $56,678,152 | |
| 7 | RVMD |
Revolution Medicines, Inc.
|
553,290 | $53,807,452 | |
| 8 | CYTK |
Cytokinetics Inc
|
779,446 | $51,373,285 |
All Filings in DSGN
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $363,707 | 34,183 | Shares | Sole | 2026-05-15 | |
| 2024-06-30 | $10,003 | 2,986 | Shares | Sole | 2024-08-14 | |
| 2022-03-31 | $329,395 | 20,396 | Shares | Sole | 2022-05-09 | |
| 2021-12-31 | $493,543 | 23,052 | Shares | Sole | 2022-02-10 | |
| No filing history on record for this holder in this stock. | ||||||